World

U.S. holding 63 million doses of hydroxychloroquine after FDA rules it doesn’t help against coronavirus

New York Daily News
By New York Daily News
1 Min Read June 18, 2020 | 6 years Ago
Go Ad-Free today

Good news for President Donald Trump — he can have all the hydroxychloroquine he wants.

The federal government suddenly finds itself with a surplus of more than 60 million doses of hydroxychloroquine now that the FDA has deemed the anti-malarial medication ineffective in treating coronavirus.

CNN reports that the government began stockpiling donated dosages in late March. That surplus also reportedly includes 2 million doses of a similar drug, chloroquine, that was donated by the Bayer company.

“I worry that history will judge this as having over-invested in one treatment pathway as opposed to looking more broadly at a larger number of treatment candidates,” School of Public Health at the University at Albany dean David Holtgrave, who co-authored a study on hydroxychloroquine and coronavirus, told CNN.

Trump and his media surrogates had long touted hydroxychloroquine as a “game changer” in efforts to contain the pandemic that has killed 120,000 Americans.

The president claimed without proof last month that he had begun taking hydroxychloroquine as a preventive measure against coronavirus. A week later, he said he had stopped using it.

The World Health Organization ended its trial of hydroxychloroquine Thursday after finding no reason to believe it is an effective treatment for covid-19, according to The Hill. The FDA reached its conclusion Tuesday.

Share

Categories:

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options